{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T17:11:19Z","timestamp":1795281079720,"version":"4.10.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early onset of action has become recognized as an important efficacy feature of preventive migraine treatment, which can help overcome adherence issues commonly associated with older medications. Preventive treatments that target the calcitonin gene-related peptide (CGRP) or the CGRP receptor have been previously shown to provide early onset of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This subanalysis of primary endpoints of two separate phase 2b\/3 studies sought to determine the onset of action of fremanezumab in Japanese and Korean patients with episodic migraine (EM) and chronic migraine (CM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In EM patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009357), both fremanezumab quarterly and fremanezumab monthly led to greater reductions in weekly migraine days (days\/week) than placebo from the first week after the initial injection and thereafter during the remainder of the study period. Similarly, CM patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009571) had a greater reduction in headache days of at least moderate severity (days\/week) with fremanezumab (total) than placebo. The percentage of patients with a migraine day (EM) or headache day at least moderate severity (CM) was lower in those treated with fremanezumab than placebo and this effect was apparent from as early as Day 2 (1 day after first injection).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that fremanezumab has an early onset of action, as noted in previous post hoc analyses of anti-CGRP monoclonal antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03303092\">NCT03303092<\/jats:ext-link>\n                      , Registered 5 October 2017,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03303079\">NCT03303079<\/jats:ext-link>\n                      , Registered 5 October 2017.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-022-01393-0","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T06:03:33Z","timestamp":1644386613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b\/3 trials in Japanese and Korean patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"issue":"10159","key":"1393_CR1","first-page":"1789","volume":"392","author":"GBD","year":"2017","unstructured":"GBD (2017) Disease and injury incidence and prevalence collaborators (2018) global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet 392(10159):1789\u20131858","journal-title":"Lancet"},{"issue":"16","key":"1393_CR2","first-page":"00126","volume":"S0025-6196","author":"DC Buse","year":"2016","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A et al (2016) Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO study. Mayo Clin Proc S0025-6196(16):00126\u201300129","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"1393_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10072-013-1378-9","volume":"34","author":"D D'Amico","year":"2013","unstructured":"D'Amico D, Grazzi L, Usai S, Leonardi M, Raggi A (2013) Disability and quality of life in headache: where we are now and where we are heading. Neurol Sci 34(Suppl 1):S1\u2013S5","journal-title":"Neurol Sci"},{"issue":"2","key":"1393_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/head.12251","volume":"54","author":"GN Ferracini","year":"2014","unstructured":"Ferracini GN, Dach F, Speciali JG (2014) Quality of life and health-related disability in children with migraine. Headache 54(2):325\u2013334","journal-title":"Headache"},{"issue":"6","key":"1393_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1046\/j.1468-2982.2003.00543.x","volume":"23","author":"RB Lipton","year":"2003","unstructured":"Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ (2003) The family impact of migraine: population-based studies in the USA and UK. Cephalalgia 23(6):429\u2013440","journal-title":"Cephalalgia"},{"issue":"1","key":"1393_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0972753120929563","volume":"27","author":"R Pradeep","year":"2020","unstructured":"Pradeep R, Nemichandra SC, Harsha S, Radhika K (2020) Migraine disability, quality of life, and its predictors. Ann Neurosci 27(1):18\u201323","journal-title":"Ann Neurosci"},{"issue":"9","key":"1393_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/0333102419835465","volume":"39","author":"M Bonafede","year":"2019","unstructured":"Bonafede M, Wilson K, Xue F (2019) Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia 39(9):1086\u20131098","journal-title":"Cephalalgia"},{"issue":"6","key":"1393_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478\u2013488","journal-title":"Cephalalgia"},{"issue":"9","key":"1393_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/head.13157","volume":"57","author":"JM Woolley","year":"2017","unstructured":"Woolley JM, Bonafede MM, Maiese BA, Lenz RA (2017) Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache 57(9):1399\u20131408","journal-title":"Headache"},{"issue":"4","key":"1393_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655","journal-title":"Headache"},{"issue":"8","key":"1393_CR11","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/j.1526-4610.2011.01986.x","volume":"51","author":"EW Loder","year":"2011","unstructured":"Loder EW, Rizzoli P (2011) Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations. Headache 51(8):1336\u20131345","journal-title":"Headache"},{"issue":"1","key":"1393_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, Kuga A, Kim Y, Cotton S et al (2019) Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20(1):68","journal-title":"J Headache Pain"},{"issue":"Suppl 3","key":"1393_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/head.13375","volume":"58","author":"E Loder","year":"2018","unstructured":"Loder E, Rizzoli P (2018) Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache 58(Suppl 3):218\u2013229","journal-title":"Headache"},{"issue":"Suppl 1","key":"1393_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10072-018-3337-y","volume":"39","author":"M Vikelis","year":"2018","unstructured":"Vikelis M, Spingos KC, Rapoport AM (2018) A new era in headache treatment. Neurol Sci 39(Suppl 1):47\u201358","journal-title":"Neurol Sci"},{"issue":"6","key":"1393_CR15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2147\/NDT.S3497","volume":"4","author":"D D'Amico","year":"2008","unstructured":"D'Amico D, Tepper SJ (2008) Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 4(6):1155\u20131167","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1393_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","volume":"19","author":"T Schwedt","year":"2018","unstructured":"Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G et al (2018) Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 19(1):92","journal-title":"J Headache Pain"},{"issue":"2","key":"1393_CR17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/head.13691","volume":"60","author":"HC Detke","year":"2020","unstructured":"Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW et al (2020) Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache 60(2):348\u2013359","journal-title":"Headache"},{"issue":"15 Supplement","key":"1393_CR18","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1212\/WNL.94.15_supplement.4014","volume":"94","author":"AP Andreou","year":"2020","unstructured":"Andreou AP, Wright P, Detke H, Ruff D, Reuter U (2020) Galcanezumab shows efficacy as early as day 1 after initial treatment vs. placebo for the prevention of episodic and chronic migraine (4014). Neurology 94(15 Supplement):4014","journal-title":"Neurology"},{"issue":"1","key":"1393_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s10194-021-01230-w","volume":"22","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E (2021) Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain 22(1):15","journal-title":"J Headache Pain"},{"issue":"10","key":"1393_CR20","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/head.13654","volume":"59","author":"PK Winner","year":"2019","unstructured":"Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M et al (2019) Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache 59(10):1743\u20131752","journal-title":"Headache"},{"issue":"7","key":"1393_CR21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092\u20131101","journal-title":"Headache"},{"issue":"7","key":"1393_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X et al (2021) Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1102\u20131111","journal-title":"Headache"},{"issue":"4","key":"1393_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1526-4610.2007.00757.x","volume":"47","author":"MF Peres","year":"2007","unstructured":"Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N et al (2007) Patients\u2019 preference for migraine preventive therapy. Headache 47(4):540\u2013545","journal-title":"Headache"},{"issue":"18","key":"1393_CR24","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine. A randomized study. Neurology 95(18):e2487\u2013e2499","journal-title":"Neurology"},{"issue":"5","key":"1393_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470\u2013485","journal-title":"Cephalalgia"},{"issue":"S2","key":"1393_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/head.13306","volume":"58","author":"J Brandes","year":"2018","unstructured":"Brandes J, Yeung PP, Aycardi E, Bigal M, Blankenbiller T, Grozinski-Wolff M et al (2018) Early onset of action with fremanezumab versus placebo for the preventive treatment of chronic migraine. 60th Annual Scientific Meeting American Headache Society\u00ae June 28\u2013July 1, 2018 San Francisco Marriott Marquis San Francisco, CA. Headache 58(S2):61\u2013215","journal-title":"Headache"},{"key":"1393_CR27","volume-title":"Very early onset of action of fremanezumab in patients with migraine and documented inadequate response to 2 to 4 classes of migraine preventive medications: results of the international, multicenter, randomized, placebo-controlled FOCUS study","author":"JL Brandes","year":"2020","unstructured":"Brandes JL, Ramirez Campos V, Yang R, Cohen JM, Galic M, Ning X et al. 2020 Very early onset of action of fremanezumab in patients with migraine and documented inadequate response to 2 to 4 classes of migraine preventive medications: results of the international, multicenter, randomized, placebo-controlled FOCUS study. Presented at the European Headache Federation (EHF) Virtual Congress"},{"key":"1393_CR28","volume-title":"Early efficacy of fremanezumab in patients with episodic and chronic migraine and inadequate response to 2 to 4 classes of migraine preventive medications due to lack of efficacy: Results of the international, multicenter, phase 3b FOCUS Study","author":"AJ Starling","year":"2020","unstructured":"Starling AJ, Ramirez Campos V, Yang R, Cohen JM, Galic M, Ning X et al. 2020 Early efficacy of fremanezumab in patients with episodic and chronic migraine and inadequate response to 2 to 4 classes of migraine preventive medications due to lack of efficacy: Results of the international, multicenter, phase 3b FOCUS Study. Presented at the European Headache Federation (EHF) Virtual Congress"},{"issue":"22","key":"1393_CR29","first-page":"365","volume":"115","author":"HC Diener","year":"2018","unstructured":"Diener HC, Holle D, Dresler T, Gaul C (2018) Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl Int 115(22):365\u2013370","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"1393_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s10194-020-01212-4","volume":"22","author":"SD Silberstein","year":"2021","unstructured":"Silberstein SD, Cohen JM, Yang R, Gandhi SK, Du E, Jann AE et al (2021) Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials. J Headache Pain 22(1):2","journal-title":"J Headache Pain"},{"issue":"20","key":"1393_CR31","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92(20):e2309\u2013e2320","journal-title":"Neurology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01393-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:43:43Z","timestamp":1726620223000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01393-0","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"5 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both trials were conducted in compliance with the International Conference on Harmonisation Good Clinical Practice Guideline and local regulatory requirements, including those related to informed consent, and were approved by an institutional review board or independent ethics committee\/ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TT has received grants or contracts from Eisai Co., Ltd. Amgen Inc., Eli Lilly Japan K.K., Allergan Japan K.K.; consulting fees from Otsuka Pharmaceutical Co., Ltd.; honoraria for lectures from Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Amgen Inc., and Eli Lilly Japan K.K. B-KK reports personal fees from Otsuka Pharmaceutical Co., Ltd.; consultation fees from Teva Korea and Sanofi Korea; consultation and lecture fees from Lundbeck Korea; and lecture fees from Lilly Korea, Allergan Korea, SK-Pharma, and YuYu Pharma Inc. XN is a full-time employee of Teva Branded Pharmaceutical Products R&D. MN, YS, MI, and NK are full-time employees of Otsuka Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}